Ergomed PLC (AIM:ERGO, ETR:2EM) (Ergomed PLC (AIM:ERGO, ETR:2EM), Ergomed PLC (AIM:ERGO, ETR:2EM)) Chief Financial Officer Richard Barfield joins Proactive to tell the market the 2021 adjusted EBITDA will be ahead of market expectations with the growth of the US business the stand-out feature of the company’s performance.
Total revenue for the 12 months advanced by 37.2% to £118.6mln, with acquisitions augmenting organic expansion. Turnover in the States was up 59.5%.
Across all metrics, Ergomed’s performance was strong: the order book was £240mln, up 24.4%, while the firm’s cash position increased by £20mln to £32.2mln.